Illumina Inc at JPMorgan Healthcare Conference Transcript
All right. Great. Welcome to the J.P. Morgan Healthcare Conference. My name is Casey Woodring from the Life Science Tools and Diagnostics team. Pleased to be joined by Illumina, CEO, Jacob Thaysen. We'll go through the corporate presentation, then we'll do some Q&A afterwards. Jacob, the floor is yours.
Thank you, Casey, J.P. Morgan and to the entire team for hosting us this year again and thank you all for joining us today. I'm Jacob Thaysen, CEO of Illumina. As a reminder, today's presentation includes forward-looking statements and non-GAAP measures. I encourage all of you to review the details in our SEC filings.
Today, I will focus on three key topics. First, I will start with where Illumina stands today and our return to growth, including a first look at our first -- fourth-quarter 2025 results. Second, I'll discuss how Illumina's differentiated ecosystem and workflow position us well to drive continued growth, especially in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

